stockrow
Saturday 7 November 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
- EPS
- −7.27%
- Free cash flow
- −7.00%
Quarter to September 2026, against a year earlier
10.19
0.52
+5.38%
Follow DSGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
16.36 | 18.45 | 21.87 | 16.84 | |
Current Ratio |
16.78 | 18.86 | 22.28 | 17.14 | |
Net Debt/EBITDA |
9.45 | 9.41 | 11.31 | 11.87 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 0.77 | 0.93 | 0.75 | |
Capex/Depreciation |
(0.10) | (0.15) | 0.00 | 0.10 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.24) | (0.25) | (0.27) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.24) | (0.25) | (0.27) | (0.21) | |
Cash per Share |
3.31 | 3.32 | 3.63 | 3.83 | |
Shareholders Equity per Share |
3.21 | 3.23 | 3.55 | 3.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.21 | 3.23 | 3.55 | 3.71 | |
Free Cash Flow |
(15.39) | (15.54) | (16.43) | (12.00) | |
Working Capital |
201.21 | 200.77 | 216.86 | 210.73 | |
Capital Expenditures |
(0.01) | (0.02) | — | (0.03) | |
Net Current Asset Value |
199.35 | 198.74 | 214.66 | 210.08 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
2.00 | 2.08 | 2.73 | 2.25 | |
Average Assets |
214.29 | 219.01 | 233.96 | 239.15 | |
Average Common Equity |
200.96 | 207.45 | 222.99 | 227.30 |
Columns are period end dates · fundamentals updated 6 Nov 2026